{"id":"W2407327553","doi":"10.1200/jco.2014.32.15_suppl.tps8615","title":"A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Ibrutinib; Medicine; Vincristine; Internal medicine; Oncology; Rituximab; CHOP; Diffuse large B-cell lymphoma; Cyclophosphamide; Lymphoma; Chemotherapy; Chronic lymphocytic leukemia; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002123543,0.00222901,0.004084897,0.0006060592,0.0008254801,0.001379321,0.001362386,0.00243801,0.01122878],"category_scores_gemma":[0.001827757,0.001149009,0.001619604,0.0006036895,0.001456522,0.001313265,0.0005222168,0.004248924,0.002318489],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007610291,"about_ca_system_score_gemma":0.001622093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001179982,"about_ca_topic_score_gemma":0.002696456,"domain_scores_codex":[0.9992439,0.0003550788,0.00003994545,0.0001816593,0.00006214209,0.000117303],"domain_scores_gemma":[0.9990337,0.000218372,0.0001814611,0.00009218513,0.000104753,0.0003694727],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.973725,0.01494908,0.000192726,0.0005063869,0.0005796853,0.0000222879,0.00003457279,0.0001176669,0.001936415,0.00006174986,0.0008151456,0.007059266],"study_design_scores_gemma":[0.9647271,0.03406083,0.0004280827,0.00001382267,0.0001498196,0.000009176716,0.000008804506,0.0001175156,0.0001032804,0.00005583416,0.0003184694,0.000007286909],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.947926,0.008822826,0.002455439,0.001652307,0.002643689,0.02646408,0.003630974,0.0006145325,0.005790188],"genre_scores_gemma":[0.9483236,0.005241272,0.004405813,0.003566895,0.001084935,0.02700165,0.002281711,0.0000873844,0.008006685],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01122878,"threshold_uncertainty_score":0.03756398,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03691613082768837,"score_gpt":0.3859590774920135,"score_spread":0.3490429466643252,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}